

# Apex Healthcare takeover deadline extended to Jan 2



## BUSINESS

Thursday, 18 Dec 2025



As of Dec 16, 2025, the total shares held by Pharmora and parties acting in concert with it was 88.02% of Apex Healthcare's shares.

PETALING JAYA: The closing date for [Apex Healthcare Bhd](#) 's voluntary takeover has been extended to Jan 2, 2026 from its earlier date of Dec 19, 2025.

In a statement, UOB Kay Hian (M) Sdn Bhd on behalf of the offerer, Pharmora Investment Holdings Pte Ltd, said all other details and conditions set out in the offer remained the same.




To recap, Pharmora had offered RM2.64 per share to acquire the shares it does not own with the aim to take the group private.

Backed by Temasek Holdings (Private) Ltd and the Employees Provident Fund, Pharmora is the special-purpose vehicle of healthcare private equity firm Quadria Capital Investment Management Pte Ltd.

The statement noted that as of Dec 16, 2025, the total shares held by Pharmora and parties acting in concert with it was 88.02% of Apex Healthcare's shares.

The offer will then become compulsory when the offer hits 90%.

Research firm [Kenanga Investment Bank Bhd](#) , which is also the group's independent adviser, has urged minority shareholders to accept the takeover offer.



### STARPICKS

Twirl into festive luxury unfold

It said the proposed cash offer of RM2.64 was deemed "fair and reasonable".

Kenanga Investment further added the offer price represented a 17% to 25% premium over the value of RM2.11 to RM2.26 per share, calculated on a fully diluted sum-of-parts basis.

It also offers a 16% premium over the one-year volume-weighted average market price of RM2.28.

At market close, Apex Healthcare's share price was recorded at RM2.62 with a market capitalisation of RM1.89bil.

For its third quarter ended Sept 30, 2025 (3Q25), Apex Healthcare's net profit dropped to RM15.6mil from RM18.23mil in the previous corresponding period.

Meanwhile, revenue dropped to RM253.20mil from RM237.37mil previously.

In a filing with the stock exchange following the announcement of its third-quarter earnings last month, the company said its core pharmaceutical manufacturing and distribution businesses continued to perform steadily through 3Q25.

